RESUMO
SARS-CoV-2 has infected more than 400 million people around the globe and caused millions of deaths. Since its identification in November 2021, Omicron, a highly transmissible variant, has become the dominant variant in most countries. Omicrons highly mutated spike protein, the main target of vaccine development, significantly compromises the immune protection from current vaccination. We develop an mRNA vaccine (SOmicron-6P) based on an Omicron-specific sequence. In mice, SOmicron-6P shows superior neutralizing antibodies inducing abilities to a clinically approved inactivated virus vaccine, a clinically approved protein subunit vaccine, and an mRNA vaccine (SWT-2P) with the same sequence of BNT162b2 RNA. Significantly, SOmicron-6P induces a 14.4[~]27.7-fold and a 28.3[~]50.3-fold increase of neutralizing activity against the pseudovirus of Omicron and authentic Omicron compared to SWT-2P, respectively. In addition, two doses SOmicron-6P significantly protects Syrian hamsters against challenge with SARS-CoV-2 Omicron variant and elicits high titers of nAbs in a dose-dependent manner in macaques. Our results suggest that SOmicron-6P offers advantages over current vaccines, and it will be helpful for those with weak immunity.
RESUMO
Objective To investigate the clinical therapeutic effect of endoscopic retrograde cholangiopancreatography(ERCP) for treating acute biliary pancreatitis (ABP). Methods 220 cases with ABP admitted in General Hospital of Northern Theater Command from January 2016 to January 2019 were enrolled. Patients were divided into endoscopy group (n=107) and non-endoscopy group (control group n=113) based on the different treatments. Blood WBC, amylase (AmyL), TBiL and ALT levels were recorded before, 1 day and 3 days after treatment. Time of abdominal pain and distention alleviation, length of stay and cost of hospitalization were compared between two groups. Results AmyL levels 1 day and 3 days after treatment in endoscopy group was significantly lower than that before treatment [( 197. 45 ± 149. 36 ), (67.39 ±42.30)U/L vs (394.45 ±582.33)U/L], and the difference was statistically different(P<0.05), but AmyL in control group was not greatly different before and after ERCP. ALT level 3 days after treatment in endoscopy and control group was significantly lower than that before treatment [(60. 94 ± 62. 44) U/L vs (162.07 ±62.53) U/L, (46.96 ± 46.75) U/L vs (186.86 ± 89.04) U/L]], and the difference was statistically different(P<0. 05). Tbil level after treatment in endoscopy group was significantly lower than that before treatment[(32. 63 ± 26. 84)μmol/L vs (164. 18 ± 64. 93)μmol/L], and the difference was statistically different(P<0. 05), but Tbil in control group was not greatly different before and after ERCP. Time of abdominal pain and distention relief [(6. 24 ± 1. 65)d vs (10. 00 ± 2. 91)d], length of stay[(8. 53 ± 5. 40)d vs (15. 84 ± 5. 05)d] and cost of hospitalization[(42685. 75 ± 14462. 10) Yuan vs (63246. 29 ± 18040. 02) Yuan] in endoscopy group were obviously decreased compared with those in control group, and the difference was statistically different(P<0. 05). Conclusions The clinical therapeutic effect of ERCP was obvious in the treatment of ABP.
